Nadroparin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Nadroparin
| |
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | ? |
| ATC code | B01 |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | Mean MW = 4500 Daltons |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
|
WikiDoc Resources for Nadroparin | |
|
Articles | |
|---|---|
|
Most recent articles on Nadroparin | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Nadroparin at Clinical Trials.gov Clinical Trials on Nadroparin at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Nadroparin
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Nadroparin Discussion groups on Nadroparin Patient Handouts on Nadroparin Directions to Hospitals Treating Nadroparin Risk calculators and risk factors for Nadroparin
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Nadroparin | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Nadroparin is a form of low molecular weight heparin.
References
- The Merck Index, 12th Edition. 6434
External links
- http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=483128
- http://www.mayoclinic.com/health/drug-information/DR600971
- Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A (2006). "A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study". Pharmacology 78 (3): 136-43. doi:10.1159/000096484. PMID 17057417.
WikiDoc Research Resources for Nadroparin | |
|---|---|
| Articles on Nadroparin | Most recent articles on Nadroparin • Most cited articles on Nadroparin • Review articles on Nadroparin • Articles on Nadroparin in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Nadroparin | Powerpoint slides on Nadroparin • Images of Nadroparin • Photos of Nadroparin • Podcasts & MP3s on Nadroparin • Videos on Nadroparin |
| Evidence Based Medicine Regarding Nadroparin | Cochrane Collaboration on Nadroparin • Bandolier on Nadroparin • TRIP on Nadroparin |
| Cost Effectiveness of Nadroparin | Cost Effectiveness of Nadroparin |
| Clinical Trials Involving Nadroparin | Ongoing Trials on Nadroparin at Clinical Trials.gov • Trial results on Nadroparin • Clinical Trials on Nadroparin at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Nadroparin | US National Guidelines Clearinghouse on Nadroparin • NICE Guidance on Nadroparin • NHS PRODIGY Guidance • FDA on Nadroparin • CDC on Nadroparin |
| Textbook Information on Nadroparin | Books and Textbook Information on Nadroparin |
| Pharmacology Resources on Nadroparin | Dosing of Nadroparin • Drug interactions with Nadroparin • Side effects of Nadroparin • Allergic reactions to Nadroparin • Overdose information on Nadroparin • Carcinogenicity information on Nadroparin • Nadroparin in pregnancy • Pharmacokinetics of Nadroparin • |
| Genetics, Pharmacogenomics, and Proteinomics of Nadroparin | Genetics of Nadroparin • Pharmacogenomics of Nadroparin • Proteomics of Nadroparin |
| Newstories on Nadroparin | Nadroparin in the news • Be alerted to news on Nadroparin • News trends on Nadroparin |
| Commentary on Nadroparin | Blogs on Nadroparin |
| Patient Resources on Nadroparin | Patient resources on Nadroparin • Discussion groups on Nadroparin • Patient Handouts on Nadroparin • Directions to Hospitals Treating Nadroparin • Risk calculators and risk factors for Nadroparin |
| Healthcare Provider Resources on Nadroparin | Symptoms of Nadroparin • Causes & Risk Factors for Nadroparin • Diagnostic studies for Nadroparin • Treatment of Nadroparin |
| Continuing Medical Education (CME) Programs on Nadroparin | CME Programs on Nadroparin |
| International Resources on Nadroparin | Nadroparin en Espanol • Nadroparin en Francais |
| Business Resources on Nadroparin | Nadroparin in the Marketplace • Patents on Nadroparin |
| Informatics Resources on Nadroparin | List of terms related to Nadroparin |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
